Strategies of Targeting CK2 in Drug Discovery: Challenges, Opportunities, and Emerging Prospects

• Published in: Journal of medicinal chemistry 2023-02, Vol.66 (4), p.2257-2281
• Main Authors: Chen, Yijia, Wang, Yuxi, Wang, Jiaxing, Zhou, Zhilan, Cao, Shu, Zhang, Jifa
• Format: Article
• Language: English
• Subjects: Antineoplastic Agents - pharmacology; Casein Kinase II; Drug Discovery; Humans; Neoplasms - drug therapy; Protein Kinase Inhibitors - pharmacology; Protein Serine-Threonine Kinases
• ISSN: 0022-2623; 1520-4804
• DOI: 10.1021/acs.jmedchem.2c01523

CK2 (casein kinase 2) is a serine/threonine protein kinase that is ubiquitous in eukaryotic cells and plays important roles in a variety of cellular functions, including cell growth, apoptosis, circadian rhythms, DNA damage repair, transcription, and translation. CK2 is involved in cancer pathogenesis and the occurrence of many diseases. Therefore, targeting CK2 is a promising therapeutic strategy. Although many CK2-specific small-molecule inhibitors have been developed, only CX-4945 has progressed to clinical trials. In recent years, novel CK2 inhibitors have gradually become a research hotspot, which is expected to overcome the limitations of traditional inhibitors. Herein, we summarize the structure, biological functions, and disease relevance of CK2 and emphatically analyze the structure–activity relationship (SAR) and binding modes of small-molecule CK2 inhibitors. We also discuss the latest progress of novel strategies, providing insights into new drugs targeting CK2 for clinical practice.